Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 2.860
+0.040 (1.42%)
Aug 28, 2026, 10:23 AM AEST
Australian Clinical Labs Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Income | 23.71 | 32.43 | 23.93 | 35.9 | 178.24 |
Depreciation & Amortization | 135.35 | 136.04 | 128.43 | 122.76 | 106.1 |
Loss (Gain) From Sale of Assets | -0.07 | 0.04 | 1.04 | -0.14 | 0.67 |
Stock-Based Compensation | 2.25 | 3.44 | 3.06 | 1.88 | 1.46 |
Other Operating Activities | -9.89 | 1.38 | 2.64 | -10.48 | 8.14 |
Change in Accounts Receivable | 5.35 | 8.32 | -7.72 | 17.4 | -28.12 |
Change in Inventory | 1.38 | 1.21 | -1.73 | 5 | -3.9 |
Change in Accounts Payable | 0.27 | -0.03 | 11.65 | -17.73 | 16.49 |
Change in Other Net Operating Assets | 4.96 | -0.04 | -1.71 | -10.91 | 5.01 |
Operating Cash Flow | 163.31 | 182.8 | 159.59 | 143.68 | 284.09 |
Operating Cash Flow Growth | -10.66% | 14.54% | 11.07% | -49.42% | 84.64% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Capital Expenditures | -9.58 | -8.41 | -6.51 | -6.93 | -21.25 |
Sale of Property, Plant & Equipment | 0.35 | 0.1 | 0.33 | 0.24 | 0.27 |
Cash Acquisitions | -0.05 | -0.58 | -1.07 | -5.48 | -51.06 |
Investing Cash Flow | -9.28 | -8.9 | -7.25 | -12.18 | -72.04 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Long-Term Debt Issued | 35 | 31 | 14 | 100.5 | - |
Total Debt Issued | 35 | 31 | 14 | 100.5 | - |
Long-Term Debt Repaid | -137.25 | -165.68 | -138.06 | -140.61 | -191.69 |
Total Debt Repaid | -137.25 | -165.68 | -138.06 | -140.61 | -191.69 |
Net Debt Issued (Repaid) | -102.25 | -134.68 | -124.06 | -40.11 | -191.69 |
Repurchase of Common Stock | -23.15 | -19.12 | -1.74 | -0.89 | -4.94 |
Common Dividends Paid | -24.59 | -24.95 | -19.95 | -96.88 | -24.22 |
Other Financing Activities | -0.7 | - | -0.39 | - | -0.06 |
Financing Cash Flow | -150.69 | -178.74 | -146.14 | -137.88 | -220.91 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Foreign Exchange Rate Adjustments | -0.05 | 0.14 | -0.03 | -0.04 | 0.01 |
Net Cash Flow | 3.29 | -4.69 | 6.18 | -6.42 | -8.86 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 153.73 | 174.39 | 153.09 | 136.75 | 262.84 |
Free Cash Flow Growth | -11.85% | 13.92% | 11.95% | -47.97% | 82.07% |
Free Cash Flow Margin | 20.88% | 23.53% | 21.98% | 19.62% | 26.40% |
Free Cash Flow Per Share | 0.80 | 0.87 | 0.77 | 0.68 | 1.30 |
Levered Free Cash Flow | 166.66 | 178.09 | 161.24 | 126.48 | 250.39 |
Unlevered Free Cash Flow | 175.83 | 187.2 | 168.85 | 134.9 | 257.74 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash Interest Paid | 18.36 | 18.46 | 16.67 | 13.85 | 11.39 |
Cash Income Tax Paid | 23.66 | 14.43 | 10.16 | 17.91 | 68.87 |
Change in Working Capital | 11.96 | 9.46 | 0.49 | -6.24 | -10.52 |